10 results on '"Mehboob T"'
Search Results
2. Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial
- Author
-
Fonseca Mdo C, Molyneux E, Ghimire S, Bhutta Za, Mahboob Mb, Resende Lv, Safdar Z, Laura Newberry, Lissauer S, Bernadette Ann-Marie O'Hare, Herbst K, Judd Tm, Jacobs Ld, Riaz T, Pafs J, A Selman, Rodrigues Rn, Musafili A, Ravindran Tk, El-Mohandes Aae, Ryon Jj, Mehboob T, Dawson P, Newell M, Jithesh, Persson La, Baribwira C, Jamshaid M, Muhwava W, Stevenson K, Omar S, Bashir I, Nishihara Y, Qomariyah N, Anggondowati T, Kiely M, Mulindwa Pa, Kennedy N, University of St Andrews. School of Medicine, University of St Andrews. Global Health Implementation Group, and University of St Andrews. Infection and Global Health Division
- Subjects
Male ,RM ,Pediatrics ,medicine.medical_specialty ,Malawi ,RJ ,Prednisolone ,Population ,NDAS ,Anti-Inflammatory Agents ,HIV Infections ,030204 cardiovascular system & hematology ,Pneumocystis carinii ,Placebos ,03 medical and health sciences ,0302 clinical medicine ,Pneumocystis jiroveci pneumonia ,SDG 3 - Good Health and Well-being ,Anti-Infective Agents ,Double-Blind Method ,Environmental health ,Case fatality rate ,Trimethoprim, Sulfamethoxazole Drug Combination ,Journal Article ,Secondary Prevention ,Medicine ,Childbirth ,Humans ,030212 general & internal medicine ,education ,education.field_of_study ,Pregnancy ,business.industry ,Mortality rate ,Pneumonia, Pneumocystis ,HIV ,RJ Pediatrics ,Infant ,medicine.disease ,Survival Analysis ,Infant mortality ,RM Therapeutics. Pharmacology ,Child mortality ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Life expectancy ,Female ,business - Abstract
Background: Pneumocystis jiroveci pneumonia (PJP) is the most common opportunistic infection in infants with vertically acquired HIV infection and the most common cause of death in HIV-infected infants.Objectives: To determine whether early administration of adjuvant corticosteroids in addition to standard treatment reduces mortality in infants with vertically acquired HIV and clinically diagnosed PJP when co-infection with cytomegalovirus and other pathogens cannot be excluded.Methods: A double-blind placebo-controlled trial of adjuvant prednisolone treatment in HIV-exposed infants aged 2–6 months admitted to Queen Elizabeth Central Hospital, Blantyre who were diagnosed clinically with PJP was performed. All recruited infants were HIV-exposed, and the HIV status of the infant was confirmed by DNA-PCR. HIV-exposed and infected infants as well as HIV-exposed but non-infected infants were included in the study. The protocol provided for the addition of prednisolone to the treatment at 48 h if there was clinical deterioration or an independent indication for corticosteroid therapy in any patient not receiving it. Oral trimethoprim-sulfamethoxazole (TMP/SMX) therapy and full supportive treatment were provided according to established guidelines. Primary outcomes for all patients included survival to hospital discharge and 6-month post-discharge survival.Results: It was planned to enroll 200 patients but the trial was stopped early because of recruitment difficulties and a statistically significant result on interim analysis. Seventy-eight infants were enrolled between April 2012 and August 2014; 36 infants (46%) were randomised to receive corticosteroids plus standard treatment with TMP/SMX, and 42 infants (54%) received the standard treatment plus placebo. In an intention-to treat-analysis, the risk ratio of in-hospital mortality in the steroid group compared with the standard treatment plus placebo group was 0.53 [95% CI 0.29–0.97, p = 0.038]. The risk ratio of mortality at 6 months was 0.63 (95% CI 0.41–0.95, p = 0.029). Two children who received steroids developed bloody stools while in hospital.Conclusion: In infants with a clinical diagnosis of PJP, early use of steroids in addition to conventional TMP/SMX therapy significantly reduced mortality in hospital and 6 months after discharge.
- Published
- 2017
3. Formulation of Aloe vera based curcumin topical gel and its in-vitro evaluation.
- Author
-
Shuja M, Majeed I, Riaz T, Ahsan Waqar M, Tabassam N, Mehboob T, and Imtiaz A
- Subjects
- Cyclooxygenase Inhibitors, Excipients chemistry, Gels chemistry, Propylene Glycols, Viscosity, Curcumin, Aloe, beta-Cyclodextrins
- Abstract
Curcumin is a polyphenolic compound obtained from the rhizome of plant. Curcuma longa possesses antioxidant, anti-inflammatory and wound-healing properties. The current study was designed to formulate an Aloe vera-based curcumin topical gel. To enhance curcumin's solubility, it was first complexed with β-cyclodextrin, given its hydrophobic nature. While Carbopol, carboxy methyl cellulose and guar gum were used in various concentrations as gelling agents for preparation of the formulations. The effect of propylene glycol as a permeation enhancer was also observed. The prepared formulations were tested for different parameters such as physical appearance, spreadability, drug content, pH, viscosity and in-vitro permeation. All the formulations were found to be stable. All formulations consisting of propylene glycol showed permeation within the range of 80-90%. The maximum percentage of drug release was observed in the formulation containing 1% Carbopol 940 as the gelling agent which also exhibited good spreadability. In comparison to gels formulated with carboxymethyl cellulose and guar gum, Carbopol 940 gels appeared more translucent. Consequently, it was concluded that curcumin's permeation improved following its complexation with β-cyclodextrin. This complex when further used for the formation of an aloe vera based topical gel with 1% Carbopol 940 and 10% propylene glycol demonstrated maximum efficacy.
- Published
- 2023
4. Thermo-Responsive Sol-Gel-Based Nano-Carriers Containing Terbinafine HCl: Formulation, In Vitro and Ex Vivo Characterization, and Antifungal Activity.
- Author
-
Bajwa M, Tabassam N, Hameed H, Irfan A, Zaman M, Khan MA, Shazly GA, Mehboob T, Riaz T, and Jardan YAB
- Abstract
The current research aims to create a sol-gel-based nanocarrier containing terbinafine formulated for transdermal delivery of the drug into the skin. Sol-gel-based nanocarriers were prepared via the cold method using poloxamer-188, poloxamer-407, and distilled water. The prepared formulation was examined for pH, gelation temperature, Fourier transform infrared spectrophotometer (FTIR) analysis, thermal stability analysis, X-ray diffraction (XRD), scanning electron microscopy (SEM), particle size analysis, zeta potential, and anti-microbial activity. The in-vitro drug release study of F1 was found to be 94%, which showed greater drug release as compared to F2 and F3. The pH of the formulation was found to be within the range applicable to the skin. The gelation temperature was detected at 28 °C. The SEM images of formulations have spotted various particles well-segregated from each other. Analysis of formulations showed a mean globule size diameter of 428 nm, zeta potential values of 0.04 mV, refractive index (1.329), and viscosity (5.94 cP). FTIR analysis confirmed various functional groups' presence in the prepared formulation. Thermal analysis has confirmed the stability of the drug within the prepared formulation. The growth of inhibition was found to be 79.2% in 60 min, which revealed that the prepared formulation has shown good permeation from the membrane. Hence, the sol-gel-based nanocarrier formulation of terbinafine was successfully developed and evaluated.
- Published
- 2023
- Full Text
- View/download PDF
5. Quantifying satisfaction among pharmacists working in Pharmaceutical Sales or Marketing and its inferential relationship with demographics: A Cross-Sectional analysis in Pakistan.
- Author
-
Butt MH, Misbah S, Ahmad A, Mehboob T, and Bashir I
- Abstract
Objectives: To quantify satisfaction among pharmacists working in pharmaceutical sales or marketing in Pakistan., Methods: A cross-sectional study was conducted among pharmacists working in pharmaceutical sales and marketing during August to November, 2019. Satisfaction score of pharmacists was considered satisfied (Score > 2.5) and dissatisfied (Score < 2.5). The maximum and minimum satisfaction score was four and one for each question respectively., Results: A total of 250 questionnaires were distributed and 200 were received back yielding a response rate of 80%. Male respondents dominated the cohort and were more satisfied (2.60 ± 0.47) as compared to females (2.31 ± 0.48) with majority were 18-30 years old and 78% had Pharm. D level of education (2.61 ± 0.47). The mean satisfaction score of participant is 2.51 with standard deviation of 0.49. The 53% of the respondents were dissatisfied with their salaries. The study dependent and independent variables are correlated with each other and significant results were seen between them. The factors associated with dissatisfaction are fear of losing job (2.19 ± 0.88), switch job (2.20 ± 0.77) and health condition (2.09 ± 0.89). Factors associated with satisfaction are positive attitude of doctor (2.91 ± 0.60), doctor consider respectful job holder (2.91 ± 0.61), enjoy work (3.01 ± 0.65), job by choice (3.12 ± 0.67) and progress in job (3.00 ± 0.74)., Conclusions: It was concluded that the respondents were dissatisfied due to number of issues including disturbance in their personal life, lack of promotion and incentives among study participants., (Copyright: © Pakistan Journal of Medical Sciences.)
- Published
- 2021
- Full Text
- View/download PDF
6. Anti myelosuppressant and hematopoietic activities of ethanolic fraction obtained from seeds of Carica papaya L.
- Author
-
Ishaque A, Khan HM, Alvi MN, Siddiqi FA, Jamshaid M, Ahsan HM, Mehboob T, Tabassam N, Aslam R, and Riaz T
- Subjects
- Animals, Erythrocyte Count, Erythrocyte Indices, Ethanol chemistry, Hematopoiesis physiology, Leukocyte Count, Platelet Count, Rats, Seeds chemistry, Carica chemistry, Doxorubicin adverse effects, Hematopoiesis drug effects, Plant Extracts chemistry, Plant Extracts pharmacology
- Abstract
Bone marrow suppression is one of the serious consequences of treatment with cytotoxic chemotherapeutic agents such as doxorubicin (DOX). It is very difficult to treat bone marrow suppression caused by anti-cancer drugs. This study was aimed to evaluate hematological effects particularly the antimyelosuppressant effects of ethanolic extract of papaya seeds at 200, 400 and 600 mg/kg daily dose for three weeks in doxorubicin induced hematopoietic suppression in rat model. Hematological parameters were assessed on weekly basis on days 0, 1, 7, 14 and 21. The alcoholic extract was found to cause remission of induced myelosuppression as indicated by a dose dependent increase in WBCs, neutrophils, lymphocytes, platelets, RBCs, Hb, hematocrit & mean corpuscular volume. However, the maximum dose (600mg/kg) of the extract showed maximum activity (p<0.05) in normalizing hematological parameters when compared with group B (induced group) and group A (controlled animals). These effects were compareable with those produced by Filgrastim 5µgm/kg used as standard or reference drug during these experiments. It is concluded from the results that papaya seeds possess myelostimulant activity and can be used to treat myelosuppression caused by chemotherapy. The drug can also be used for curing anemia, thrombocytopenia and immunological disorders characterized by myelosuppression.
- Published
- 2020
7. Current burden on healthcare systems in low- and middle-income countries: recommendations for emergency care of COVID-19.
- Author
-
Hamid H, Abid Z, Amir A, Rehman TU, Akram W, and Mehboob T
- Abstract
Competing Interests: Conflicts of Interest Husnain Hamid, Zubia Abid, Attiya Amir, Touseef ur Rehman, Waqas Akram, Tooba Mehboob have no conflicts of interest that are directly relevant to the content of this article.
- Published
- 2020
- Full Text
- View/download PDF
8. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
- Author
-
Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, and Moinuddin M
- Subjects
- Child, Preschool, Female, Humans, Hydroxyurea adverse effects, Male, Polymorphism, Genetic, Prospective Studies, beta-Thalassemia blood, beta-Thalassemia enzymology, Deoxyribonucleases, Type II Site-Specific genetics, Hydroxyurea therapeutic use, beta-Thalassemia drug therapy, beta-Thalassemia genetics
- Abstract
β-thalassemia is characterized by impaired β-chain synthesis leading to ineffective erythropoiesis, severe anemia, and a need for blood transfusion. Presence of Xmn I polymorphism (-158 C-T nucleotide change) in γ-globin gene is associated with a higher fetal hemoglobin and a lesser clinical severity. This prospective study attempted to find out the effect of hydroxyurea (HU) on β-thalassemia patients in the presence or absence of Xmn I polymorphism. A total of 143 consecutive β-thalassemia patients received HU (16 mg/kg/d). Sixty-four (44.7%) had Xmn I polymorphism (either homozygous or heterozygous). Patients were evaluated at a median duration of 3 years (range, 6 mo to 9 y). Responders became transfusion independent after 6 months, partial responders had a least 50% reduction in transfusion requirement and nonresponders had no significant reduction. Of the 64 patients with Xmn I polymorphism, 44 (69%) showed response (P<0.01), whereas in those who lacked Xmn I polymorphism (n=79), only 17 (21%) were responders. This study showed that the presence of Xmn I polymorphism in β-thalassemia is a predictor of response to HU and highlights the possibility of managing this subset of patients without blood transfusion.
- Published
- 2013
- Full Text
- View/download PDF
9. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
- Author
-
Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, and Mehboob T
- Subjects
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Hydroxyurea adverse effects, Infant, Male, Nucleic Acid Synthesis Inhibitors adverse effects, Treatment Outcome, Young Adult, Erythrocyte Transfusion statistics & numerical data, Hydroxyurea administration & dosage, Nucleic Acid Synthesis Inhibitors administration & dosage, beta-Thalassemia drug therapy
- Abstract
Background: Packed red blood cell (PRC) transfusion with iron chelation is the mainstay of treatment for β-thalassemia major. This prospective interventional trial serves as a follow up to our similar earlier study that evaluated the efficacy and safety of hydroxyurea (HU) in minimizing PRC transfusions in patients with β-thalassemia major., Methods: One hundred fifty-two patients with β-thalassemia major received HU at a mean dose of 16 mg/kg/d. The results were analyzed at the end of 24 months. Transfusion requirement during the 6 months preceding the study was considered as the control., Results: One hundred forty-six of 152 patients were evaluated after 24 months of follow up; 6 patients were either lost to follow-up or withdrew consent. Grade 1 myelosuppression was observed in 4 patients and diarrhea in 2 patients. Sixty children (41%) did not require any transfusion after using HU; 57 patients (39%) showed partial response with greater than 50% reduction in PRC transfusion; and 29 patients (20%) were nonresponders with less than 50% reduction in PRC transfusion. The mean volume of PRC transfused was reduced for all patients., Conclusions: HU was found to be safe in patients with β-thalassemia major, and resulted in the reduction of transfusion requirement and in an increase in the interval between transfusions.
- Published
- 2011
- Full Text
- View/download PDF
10. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
- Author
-
Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, and Mehboob T
- Subjects
- Adolescent, Child, Child, Preschool, Erythrocyte Transfusion, Female, Humans, Male, Pakistan, beta-Thalassemia therapy, Antisickling Agents therapeutic use, Hydroxyurea therapeutic use, beta-Thalassemia drug therapy
- Abstract
Background: Packed red blood cell (PRC) transfusion with iron chelation is the mainstay of treatment for patients with beta-thalassemia major. Hemoglobin F augmentation is another approach to treat this hemoglobinopathy. This study evaluates the efficacy and safety of hydroxyurea (HU) in minimizing PRC transfusions in patients with beta-thalassemia major., Method: Twenty-three patients with beta-thalassemia major received HU at a mean dose of 16 mg/kg/d. The results were analyzed at the end of 24 months. Transfusion requirement during the 6 months preceding the study was considered as the control., Result: Twenty patients were evaluable after 24 months. The mean volume of PRC transfused was reduced from 2126.45 mL to 1489.59 mL (P<0.001). The interval between transfusions was increased by 68.7%. Grade I myelosuppression was observed in 4 patients and diarrhea in 2 patients., Conclusions: HU was found to be safe in patients with beta-thalassemia major, and resulted in reduction in the transfusion requirements and in increase of the intervals between transfusions.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.